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Introduction {#sec1}
============

Sleep problems are the core components of mood disorders, such as bipolar disorder characterized by periods of depression and mania ([@bib4]). The clinical criteria for mania include persistently elevated mood or energy and decreased need for sleep ([@bib3]). In humans, infarctions of the midbrain or pontine areas induces secondary mania ([@bib2], [@bib7], [@bib16], [@bib46], [@bib47]). In the present study, we focused on the ventral medial midbrain/pons (VMP) area, a region that contains sleep-regulating GABAergic neurons ([@bib11], [@bib50], [@bib58]). To elucidate the physiologic functions of VMP GABAergic neurons, we selectively ablated these neurons in mice with Cre-dependent viral expression of the diphtheria toxin subunit A (DTA) in the VMP of vesicular GABA transporter (VGAT; a marker of GABAergic neurons) Cre mice (VGAT-Cre^DTA/VMP^ mice: [Figures 1](#fig1){ref-type="fig"}A and 1B). For controls, we prepared mice expressing humanized *Renilla reniformis*-derived green fluorescent protein (hrGFP) in the VMP GABAergic neurons (VGAT-Cre^hrGFP/VMP^). These mice were subjected to a comprehensive behavioral test battery including various tasks that are reliably used to assess locomotor activity, depression-like behavior, sociability, anxiety, species-typical behavior, and learning and memory ([@bib13], [@bib14]).Figure 1Selective Ablation of the VMP GABAergic Neurons Induces Hyperactivity, Anti-depressive Behaviors, and Reduced Anxiety(A) VGAT-Cre mice were injected with AAV-FLEX-hrGFP (VGAT-Cre^hrGFP/VMP^ mice; control) or AAV-FLEX-DTA (VGAT-Cre^DTA/VMP^ mice) into the VMP region.(B) Brain sections stained against VGAT mRNA. VMP GABAergic neurons were selectively ablated in VGAT-Cre^DTA/VMP^ mice but not in VGAT-Cre^hrGFP/VMP^ mice. RN, red nucleus; VTA, ventral tegmental area; SN, substantia nigra; IP, interpeduncular nucleus. Scale bar, 500 μm.(C) Representative path traces and total distance traveled in the open field test. Two-tailed unpaired *t* test, *t* = 4.418, *df* = 17, *p* = 0.0004.(D) Immobility time in the tail suspension test. Two-tailed unpaired *t* test, *t* = 3.238 *df* = 17, *p* = 0.0048.(E) Immobility time in the forced swim test. Two-tailed Mann-Whitney *U* test, *U* = 0, *p* \< 0.0001.(F) Sociability and social interaction test. Preference for the zone with mouse chamber compared with the empty chamber. Two-tailed unpaired *t* test, *t* = 2.319, *df* = 17, *p* = 0.0331.(G) Time in open arms in the elevated plus maze. Two-tailed unpaired *t* test, *t* = 3.214, *df* = 16, *p* = 0.0054.(H) Nest-building scores. Two-tailed unpaired *t* test, *t* = 4.52, *df* = 17, *p* = 0.0003.(I) Exploratory preference toward familiar or novel objects in the novel object recognition task on the test day. VGAT-Cre^hrGFP/VMP^: two-tailed unpaired *t* test, *t* = 4.742, *df* = 18, *p* = 0.0002. VGAT-Cre^DTA/VMP^: two-tailed unpaired *t* test, *t* = 1.592, *df* = 16, *p* = 0.1308.(J) Total number of entries into each arm and spontaneous alternation rates in the Y-maze task. Number of arm entries: two-tailed unpaired *t* test, *t* = 3.159, *df* = 17, *p* = 0.0057. Spontaneous alternation rate: two-tailed unpaired *t* test, *t* = 1.165, *df* = 17, *p* = 0.2601.(C−J) *n* = 8--10 mice for each group. Individual values are plotted in the graphs. Data are presented as the mean ± SEM. n.s., not significant, ∗*p* \< 0.05, ∗∗*p* \< 0.01, ∗∗∗*p* \< 0.001, ∗∗∗∗*p* \< 0.0001.

Results {#sec2}
=======

GABAergic VMP Ablation Induces Hyperactivity, Anti-depressive Behaviors, and Reduced Anxiety {#sec2.1}
--------------------------------------------------------------------------------------------

Our behavioral test battery revealed that VGAT-Cre^DTA/VMP^ mice exhibited increased locomotor activity with a longer distance traveled in the open field test compared with control VGAT-Cre^hrGFP/VMP^ mice (*p* \< 0.001, [Figure 1](#fig1){ref-type="fig"}C). VGAT-Cre^DTA/VMP^ mice also showed consistently decreased immobility in both the tail suspension test (*p* \< 0.01, [Figure 1](#fig1){ref-type="fig"}D) and the forced swim test (*p* \< 0.0001, [Figure 1](#fig1){ref-type="fig"}E), suggesting anti-depressive behaviors. In addition, VGAT-Cre^DTA/VMP^ mice exhibited increased preference for the zone with mice compared with control VGAT-Cre^hrGFP/VMP^ mice (*p* \< 0.05, [Figure 1](#fig1){ref-type="fig"}F). In the elevated plus maze, VGAT-Cre^DTA/VMP^ mice spent more time in the open arms (*p* \< 0.01, [Figure 1](#fig1){ref-type="fig"}G), indicating less anxiety and increased risk-taking behavior. In addition, VGAT-Cre^DTA/VMP^ mice had lower scores in the nest building test (*p* \< 0.001, [Figure 1](#fig1){ref-type="fig"}H). We also assessed learning and memory. In the novel object recognition task, control VGAT-Cre^hrGFP/VMP^ mice showed increased exploratory preference for novel objects (*p* \< 0.001, [Figure 1](#fig1){ref-type="fig"}I). On the other hand, VGAT-Cre^DTA/VMP^ mice demonstrated no preference for novel objects (not significant, n.s., *p* = 0.131, [Figure 1](#fig1){ref-type="fig"}I), suggesting impaired novel object recognition. Conversely, in the Y maze as a test for working memory, VGAT-Cre^DTA/VMP^ mice exhibited no difference from control mice in spontaneous alternation rate (n.s., *p* = 0.260, [Figure 1](#fig1){ref-type="fig"}J), but the number of entries into each arm was increased, consistent with their hyperactivity (*p* \< 0.01, [Figure 1](#fig1){ref-type="fig"}J). Overall, the series of behavioral tests provided us landmark information to support the involvement of VMP GABAergic neurons in the various aspects of manic episodes described in both humans and rodent models ([@bib3], [@bib29], [@bib40], [@bib56]), including hyperactivity, reduced depression and anxiety, and risk-taking behavior. Together with these core components, one of the prominent symptoms of mania is a decreased need for sleep ([@bib3], [@bib54]), which helps to discriminate mania from other disorders with hyperactivity, e.g., attention-deficit/hyperactivity disorder ([@bib33]). Therefore, we next performed a detailed analysis of the sleep/wake behaviors in VGAT-Cre^DTA/VMP^ mice.

GABAergic VMP Ablation Induces Reduced Daily Sleep Amounts and Loss of Rebound Sleep {#sec2.2}
------------------------------------------------------------------------------------

Sleep consists of rapid eye movement sleep (REMS) and slow-wave sleep (SWS), also known as non-REM sleep, which are distinguished on the basis of electroencephalography (EEG) and electromyography (EMG) characteristics. It is commonly considered that sleep need is represented during SWS as EEG power in delta frequency (0.5--4 Hz), which increases in animals after prolonged wakefulness ([@bib15], [@bib27]) as well as in mutant mice with prolonged daily sleep amount ([@bib18], [@bib23]). We first measured the daily sleep amount of VGAT-Cre^DTA/VMP^ mice. The VGAT-Cre^DTA/VMP^ mice displayed reduced sleep amounts and increased wake amounts compared with control VGAT-Cre^hrGFP/VMP^ mice (SWS 24 h: *p* \< 0.0001, SWS light: *p* \< 0.0001, SWS dark: *p* \< 0.001, wake 24 h: *p* \< 0.0001, wake light: *p* \< 0.0001, wake dark: *p* \< 0.001, REMS 24 h: *p* \< 0.001, REMS light: *p* \< 0.0001, REMS dark: *p* \< 0.05, [Figures 2](#fig2){ref-type="fig"}A and 2B), consistent with our previous study ([@bib50]). Next, we calculated the delta power during daily SWS to evaluate the mean level of sleep need. In contrast to the severe sleep reduction in VGAT-Cre^DTA/VMP^ mice, there was no difference in the EEG power spectra (*p* = 0.650, [Figure S1](#mmc1){ref-type="supplementary-material"}) and the delta power (*p* = 0.378, [Figure 2](#fig2){ref-type="fig"}C) during SWS over 24 h compared with control VGAT-Cre^hrGFP/VMP^ mice. This finding suggests that VGAT-Cre^DTA/VMP^ mice are able to maintain the same level of sleep need compared with control mice, despite lower daily sleep amounts. Alternatively, although the daily sleep amount is constantly reduced, it would be an adequate amount for VGAT-Cre^DTA/VMP^ mice such that it does not evoke changes in the mean level of the SWS delta power. Thus, VGAT-Cre^DTA/VMP^ mice may not be under higher sleep pressure or suffering from greater "sleepiness" despite the reduced sleep amounts. To further investigate sleep/wake phenotypes, we performed sleep deprivation (SD) experiments.Figure 2Selective Ablation of the VMP GABAergic Neurons Induces Reduced Daily Sleep Amounts and Loss of Sleep Rebound(A) EEG, EMG, EEG delta power, and wake/REMS/SWS hypnogram. SD, sleep deprivation.(B) Total time in SWS, wake, and REMS during 24 h, light and dark periods on the baseline day. SWS 24 h: two-tailed unpaired *t* test, *t* = 6.484, *df* = 12, *p* \< 0.0001. SWS light: two-tailed unpaired *t* test, *t* = 7.579, *df* = 12, *p* \< 0.0001. SWS dark: two-tailed unpaired *t* test, *t* = 5.06, *df* = 12, *p* = 0.0003. Wake 24 h: two-tailed unpaired *t* test, *t* = 6.503, *df* = 12, *p* \< 0.0001. Wake light: two-tailed unpaired *t* test, *t* = 7.855, *df* = 12, *p* \< 0.0001. Wake dark: two-tailed unpaired *t* test, *t* = 4.756, *df* = 12, *p* = 0.0005. REMS 24 h: two-tailed unpaired *t* test, *t* = 5.231, *df* = 12, *p* = 0.0002. REMS light: two-tailed unpaired *t* test, *t* = 6.736, *df* = 12, *p* \< 0.0001. REMS dark: two-tailed unpaired *t* test, *t* = 2.2, *df* = 12, *p* = 0.0481.(C) Average of delta power (%) during SWS across 24 h on the baseline day. Two-tailed unpaired *t* test, *t* = 0.9161, *df* = 12, *p* = 0.3777.(D) Sleep rebound. Time in SWS during 4 h (20:00--24:00) *ad libitum* sleep (baseline) and after SD. VGAT-Cre^hrGFP/VMP^: two-tailed paired *t* test, *t* = 4.266, *df* = 7, *p* = 0.0037. VGAT-Cre^DTA/VMP^: two-tailed paired *t* test, *t* = 0.4298, *df* = 5, *p* = 0.6852.(E) Latency to first SWS episode after SD. Two-tailed unpaired *t* test, *t* = 2.579, *df* = 11, *p* = 0.0256.(F) Time course of delta power change during SWS after SD compared with baseline delta power. Baseline delta power is the averaged absolute value of delta power during SWS across 24 h on the baseline day. Two-way repeated measures ANOVA followed by Sidak\'s multiple comparisons. *F* (1, 11) = 0.00004835, *p* = 0.9946, the main effect of viral transduction. *F* (4, 44) = 12.87, *p* \< 0.0001, the main effect of time. VGAT-Cre^hrGFP/VMP^: 0--10 min versus 30--40 min, *p* = 0.0012; 0--10 min versus 40--50 min, *p* = 0.0002. VGAT-Cre^DTA/VMP^: 0--10 min versus 30--40 min, *p* = 0.0323; 0--10 min versus 40--50 min, *p* = 0.0041.(G) Time course of delta power change during wake after SD compared with baseline delta power. Baseline delta power is the averaged absolute value of delta power during wake across 24 h on the baseline day. Two-way repeated measures ANOVA. *F* (1, 9) = 0.3214, *p* = 0.5846, the main effect of viral transduction. *F* (4, 36) = 2.341, *p* = 0.0735, the main effect of time.(B−G) *n* = 5--8 mice for each group. Individual values are plotted in the graphs. Data are presented as the mean ± SEM. n.s., not significant, ∗*p* \< 0.05, ∗∗*p* \< 0.01, ∗∗∗*p* \< 0.001, ∗∗∗∗*p* \< 0.0001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Prolonged wakefulness with SD leads to an increase in the sleep period by so-called sleep homeostasis ([@bib6], [@bib22]) among animals. In this study, a normal sleep rebound after SD was observed in control VGAT-Cre^hrGFP/VMP^ mice (*p* \< 0.01, [Figure 2](#fig2){ref-type="fig"}D), whereas VGAT-Cre^DTA/VMP^ mice did not exhibit sleep rebound after 4-h SD (n.s., *p* = 0.685, [Figure 2](#fig2){ref-type="fig"}D), suggesting less sleep pressure after SD in VGAT-Cre^DTA/VMP^ mice.

Although the sleep latency after SD was extended in VGAT-Cre^DTA/VMP^ mice (*p* \< 0.05, [Figure 2](#fig2){ref-type="fig"}E), we found that EEG delta power during SWS was increased after SD and dissipated along with SWS time (not total time) in VGAT-Cre^DTA/VMP^ mice (0--10 min versus 30--40 min: *p* \< 0.05, 0--10 min versus 40--50 min: *p* \< 0.01, [Figure 2](#fig2){ref-type="fig"}F), despite lacking sleep rebound ([Figure 2](#fig2){ref-type="fig"}D). These data suggest that the mechanisms regulating delta power during SWS and sleep amounts are dissociable, consistent with findings from a previous study ([@bib49]). Remarkably, SWS delta power dissipation along with SWS time after SD was noticeably similar between VGAT-Cre^DTA/VMP^ and the control VGAT-Cre^hrGFP/VMP^ mice (n.s., *p* = 0.995, the main effect of viral transduction, ANOVA; [Figure 2](#fig2){ref-type="fig"}F). In contrast, the gradual decay of delta power was not observed during wakefulness (n.s., *p* = 0.074, the main effect of time, ANOVA; [Figure 2](#fig2){ref-type="fig"}G). These observations suggest that the neural mechanisms generate delta power after SD function mainly during SWS and pause during wakefulness. Overall, we revealed that VMP GABAergic neurons have critical roles in the regulation of both daily sleep amounts and homeostatic sleep as a response to SD.

Dopamine D~2~ Receptors Mediate Sleep Reduction Induced by GABAergic VMP Ablation {#sec2.3}
---------------------------------------------------------------------------------

Our previous pharmacologic study suggested that D~2~ and/or D~3~ receptors mediate the wake-promoting effect induced by ablating or inhibiting VMP GABAergic neurons ([@bib50]). To evaluate the involvement of D~2~ receptors (D~2~R) in notable behaviors in VGAT-Cre^DTA/VMP^ mice, we generated D~2~R knockout (KO) mice using fertilized egg donors of VGAT-Cre mice by the CRISPR-Cas9 technique (VGAT-Cre;D~2~R^−/−^ mice; [Figure 3](#fig3){ref-type="fig"}A). We first histologically confirmed that immunostaining for D~2~R was only detected in VGAT-Cre;D~2~R^+/+^ mice and not in VGAT-Cre;D~2~R^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}B). To verify an *in vivo* functional D~2~R deficit, we administered a moderate dose (45 mg/kg) of modafinil, a dopamine transporter blocker that has an arousal effect and is largely ineffective in D~2~R-deficient mice ([@bib42]). Consistent with the previous study, our newly generated VGAT-Cre;D~2~R^−/−^ mice did not exhibit arousal after modafinil administration (*p* = 0.788, [Figure 3](#fig3){ref-type="fig"}C), in contrast to the significant arousal effect observed in VGAT-Cre;D~2~R^+/+^ mice (*p* \< 0.001, [Figure 3](#fig3){ref-type="fig"}C).Figure 3Generation of D~2~R Knockout VGAT-Cre Mice by the CRISPR/Cas9 System(A) Schematic of CRISPR/Cas9-mediated D~2~R gene knockout using the fertilized egg donor of VGAT-Cre mice. The CRISPR target including the PAM sequence (total 23 bp) contains the part of intron 2 and exon 3 of the D~2~R gene encompassing the splicing acceptor (SA) site. ssODN, single-stranded oligodeoxynucleotide.(B) Histologic verification of D~2~R knockout. Immunostained D~2~R signals were only detected in D~2~R^+/+^ mice and not in D~2~R^−/--^ mice. Ctx, cortex; CPu, caudate putamen (striatum). Scale bar represents 1,000 μm.(C) *In vivo* functional verification of D~2~R knockout based on the loss of modafinil-induced arousal in D~2~R^−/−^ mice. D~2~R^+/+^: two-tailed paired *t* test, *t* = 9.164, *df* = 4, *p* = 0.0008. D~2~R^−/−^: two-tailed paired *t* test, *t* = 0.2872, *df* = 4, *p* = 0.7882. *n* = 5 mice for each group. Individual values are plotted in the graphs.Data are presented as the mean ± SEM. n.s., not significant, ∗∗∗*p* \< 0.001.

To assess the D~2~R involvement in sleep behaviors in VGAT-Cre^DTA/VMP^ mice, we next injected AAV-FLEX-DTA or control AAV-FLEX-hrGFP virus into the VMP of VGAT-Cre;D~2~R^+/+^ mice or VGAT-Cre;D~2~R^−/−^ mice. We first confirmed that VGAT-Cre^DTA/VMP^;D~2~R^+/+^ mice exhibited reduced amounts of SWS over 24 h (*p* \< 0.0001, the main effect of viral transduction, ANOVA; [Figure 4](#fig4){ref-type="fig"}A) in both light and dark periods (light: *p* \< 0.001, dark: *p* \< 0.01, [Figure 4](#fig4){ref-type="fig"}B) compared with control VGAT-Cre^hrGFP/VMP^;D~2~R^+/+^ mice. Although VGAT-Cre^DTA/VMP^;D~2~R^−/−^ mice also showed reduced SWS amounts over 24 h (*p* \< 0.001, the main effect of viral transduction, ANOVA; [Figure 4](#fig4){ref-type="fig"}C), strikingly, VGAT-Cre^DTA/VMP^;D~2~R^−/−^ mice showed no difference in SWS amounts during the light period compared with control VGAT-Cre^hrGFP/VMP^;D~2~R^−/−^ mice (light: n.s., *p* = 0.182, dark: *p* \< 0.001, [Figure 4](#fig4){ref-type="fig"}D). In other words, the reduced sleep amounts observed in VGAT-Cre^DTA/VMP^ mice during the light period ([Figure 2](#fig2){ref-type="fig"}B) were functionally rescued by the loss of D~2~R. This finding indicates that the sleep reduction induced by ablating VMP GABAergic neurons is mainly mediated by D~2~R.Figure 4Dopamine D~2~R Mediate Sleep Reduction Induced by GABAergic VMP Ablation(A) Hourly SWS amounts in D~2~R^+/+^ mice. Two-way repeated measures ANOVA followed by Sidak\'s multiple comparisons. *F* (1, 9) = 139.5, *p* \< 0.0001, the main effect of viral transduction.(B) Total SWS amounts in D~2~R^+/+^ mice. Light: two-tailed unpaired *t* test, *t* = 6.057, *df* = 9, *p* = 0.0002. Dark: two-tailed Mann-Whitney *U* test, *U* = 0, *p* = 0.0043.(C) Hourly SWS amounts in D~2~R^−/−^ mice. Two-way repeated measures ANOVA followed by Sidak\'s multiple comparisons. *F* (1, 9) = 24.86, *p* = 0.0008, the main effect of viral transduction.(D) Total SWS amounts in D~2~R^−/−^ mice. Light: two-tailed unpaired *t* test, *t* = 1.447, *df* = 9, *p* = 0.1817. Dark: two-tailed unpaired *t* test, *t* = 6.14, *df* = 9, *p* = 0.0002.(E) Sleep rebound. Time in SWS during 4 h (20:00--24:00) *ad libitum* sleep (baseline) and after SD. VGAT-Cre^hrGFP/VMP^;D~2~R^+/+^: two-tailed paired *t* test, *t* = 8.863, *df* = 5, *p* = 0.0003. VGAT-Cre^DTA/VMP^;D~2~R^+/+^: two-tailed paired *t* test, *t* = 2.042, *df* = 4, *p* = 0.1107. VGAT-Cre^hrGFP/VMP^;D~2~R^−/−^: two-tailed paired *t* test, *t* = 4.091, *df* = 5, *p* = 0.0094. VGAT-Cre^DTA/VMP^;D~2~R^−/−^: two-tailed paired *t* test, *t* = 0.9074, *df* = 5, *p* = 0.4058.(F) Latency to first SWS episode after SD. D~2~R^+/+^: two-tailed unpaired *t* test, *t* = 2.902, *df* = 9, *p* = 0.0175. D~2~R^−/−^: two-tailed unpaired *t* test, *t* = 2.287, *df* = 10, *p* = 0.0452.(G) Total distance traveled in the open field test. D~2~R^+/+^: two-tailed unpaired *t* test, *t* = 3.411, *df* = 18, *p* = 0.0031. D~2~R^−/−^: two-tailed unpaired *t* test, *t* = 2.261, *df* = 18, *p* = 0.0364.(H) Immobility time in the tail suspension test. D~2~R^+/+^: two-tailed unpaired *t* test, *t* = 3.064, *df* = 30, *p* = 0.0046. D~2~R^−/−^: two-tailed Mann-Whitney *U* test, *U* = 45.5, *p* = 0.0007.(I) Immobility time in the forced swim test. D~2~R^+/+^: two-tailed unpaired *t* test, *t* = 4.952, *df* = 30, *p* \< 0.0001. D~2~R^−/−^: two-tailed Mann-Whitney *U* test, *U* = 42.5, *p* = 0.0004.(J) Schematic model. VMP GABAergic neurons involved in the genesis of mania-like behaviors, including hyperactivity, anti-depressive behaviors, and reduced sleep. The reduced sleep amounts due to dysfunction of VMP GABAergic neurons were mediated in a D~2~R-dependent manner.(A−I) *n* = 5--17 mice for each group. Individual values are plotted in the graphs. Data are presented as the mean ± SEM. n.s., not significant, ∗*p* \< 0.05, ∗∗*p* \< 0.01, ∗∗∗*p* \< 0.001, ∗∗∗∗*p* \< 0.0001.

We next examined the effect of SD, which resulted in the loss of rebound sleep by ablation of VMP GABAergic neurons regardless of D~2~R^+/+^ or D~2~R^−/−^ conditions (*p* = 0.111, VGAT-Cre^DTA/VMP^;D~2~R^+/+^ basal versus SD; *p* = 0.406, VGAT-Cre^DTA/VMP^;D~2~R^−/−^ basal versus SD; [Figure 4](#fig4){ref-type="fig"}E), suggesting that the impaired sleep homeostasis in VGAT-Cre^DTA/VMP^ mice ([Figure 2](#fig2){ref-type="fig"}D) is D~2~R independent. Similarly, the extended latency to SWS after SD ([Figure 2](#fig2){ref-type="fig"}E) was D~2~R-independent (*p* \< 0.05, VGAT-Cre^hrGFP/VMP^;D~2~R^+/+^ versus VGAT-Cre^DTA/VMP^;D~2~R^+/+^; *p* \< 0.05, VGAT-Cre^hrGFP/VMP^;D~2~R^−/−^ versus VGAT-Cre^DTA/VMP^;D~2~R^−/−^; [Figure 4](#fig4){ref-type="fig"}F).

We then assessed VGAT-Cre^DTA/VMP^ mice in a set of behavioral tasks to examine the D~2~R dependency of hyperactivity and anti-depressive behaviors. In the open field test, both VGAT-Cre^DTA/VMP^;D~2~R^+/+^ and VGAT-Cre^DTA/VMP^;D~2~R^−/−^ mice exhibited increased travel distance (*p* \< 0.01, VGAT-Cre^hrGFP/VMP^;D~2~R^+/+^ versus VGAT-Cre^DTA/VMP^;D~2~R^+/+^; *p* \< 0.05, VGAT-Cre^hrGFP/VMP^;D~2~R^−/−^ versus VGAT-Cre^DTA/VMP^;D~2~R^−/−^; [Figure 4](#fig4){ref-type="fig"}G) demonstrating that the hyperactivity in VGAT-Cre^DTA/VMP^ mice ([Figure 1](#fig1){ref-type="fig"}C) is D~2~R independent. Consistently, a decreased immobility in both the tail suspension test and forced swim test was observed regardless of D~2~R^+/+^ or D~2~R^−/−^ conditions (tail suspension: *p* \< 0.01, VGAT-Cre^hrGFP/VMP^;D~2~R^+/+^ versus VGAT-Cre^DTA/VMP^;D~2~R^+/+^; *p* \< 0.001, VGAT-Cre^hrGFP/VMP^;D~2~R^−/−^ versus VGAT-Cre^DTA/VMP^;D~2~R^−/−^; [Figure 4](#fig4){ref-type="fig"}H; and forced swim: *p* \< 0.0001, VGAT-Cre^hrGFP/VMP^;D~2~R^+/+^ versus VGAT-Cre^DTA/VMP^;D~2~R^+/+^; *p* \< 0.001, VGAT-Cre^hrGFP/VMP^;D~2~R^−/−^ versus VGAT-Cre^DTA/VMP^;D~2~R^−/−^, [Figure 4](#fig4){ref-type="fig"}I), suggesting that the phenotypes consistent with anti-depressive behaviors in VGAT-Cre^DTA/VMP^ mice ([Figures 1](#fig1){ref-type="fig"}D and 1E) are also D~2~R independent.

Discussion {#sec3}
==========

In the present study, we found that ablating GABAergic neurons in the VMP induced various behavioral phenotypes, including hyperactivity, reduced depression and anxiety, loss of sleep rebound, and reduced sleep. The phenotypes in VGAT-Cre^DTA/VMP^ mice with hyperactivity in the open field ([Figure 1](#fig1){ref-type="fig"}C), reduced immobility in tail suspension ([Figure 1](#fig1){ref-type="fig"}D) and forced swim tests ([Figure 1](#fig1){ref-type="fig"}E), and increased social interaction ([Figure 1](#fig1){ref-type="fig"}F) may be consistent with the facets of mania symptoms in humans, such as increased goal-directed activity and psychomotor agitation, which is described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) ([@bib3], [@bib26]). Hyperactivity and reduced depression are common features in the reported genetic mouse models of mania, including *Shank3*-overexpression ([@bib20]) and *GSK3-β*-overexpression mutants ([@bib41]). Importantly, objectively measured high locomotor activity in manic patients quantitively bears a resemblance to the hyperactivity in hyperdopaminergic rodent models on the basis of cross-species translational studies ([@bib40], [@bib56], [@bib55]). Further, activation of dopaminergic neurons in the ventral tegmental area (VTA) induces hyperactivity in rodents ([@bib5]). Because the VTA region is anatomically included in the VMP ([Figure 1](#fig1){ref-type="fig"}B), ablation of VMP GABAergic neurons may unlock inhibitory outputs on VTA dopaminergic neurons, which could lead to locomotor hyperactivity. To further dissect the detailed mechanisms underlying hyperactivity phenotypes in future studies, dopamine levels should be measured around the nucleus accumbens, a major target area of the VTA, in VGAT-Cre^DTA/VMP^ mice. The reduced anxiety and increased risk-taking behavior of VGAT-Cre^DTA/VMP^ mice in the elevated plus maze ([Figure 1](#fig1){ref-type="fig"}G) are presumably related to excessive involvement in activities with a high potential for a painful consequence in humans ([@bib3], [@bib28]). Increased risk-taking behaviors are also reported in both manic patients and dopamine transporter knockdown (DAT-KD) hyperdopaminergic mice using comparable tasks ([@bib53], [@bib57]). In addition, the low nest-building performance ([Figure 1](#fig1){ref-type="fig"}H) supports the aspect of distractibility described in the diagnostic criteria ([@bib3], [@bib37], [@bib54]). VGAT-Cre^DTA/VMP^ mice exhibited impaired novel object recognition ([Figure 1](#fig1){ref-type="fig"}I), whereas alternation rate in the Y-maze was intact, suggesting that VGAT-Cre^DTA/VMP^ mice could remember and refer to the location of the arm they entered previously as working memory during the task. In contrast to the Y maze task, the novel object recognition task has a 24-h test interval (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}), allowing mice to have sleep states and suggesting the possible contribution of sleep to memory consolidation in this specific task. Sleep deprivation or disruption impairs the performance of novel object recognition in mice ([@bib39], [@bib44]). Thus, the reduced sleep in VGAT-Cre^DTA/VMP^ mice may account for their impaired performance in the novel object recognition task. The largely abolished daily sleep amounts in VGAT-Cre^DTA/VMP^ mice ([Figures 2](#fig4){ref-type="fig"}A and 2B) are consistent with decreased need for sleep in manic individuals ([@bib3], [@bib54]) and *ClockΔ19* mutant mice ([@bib34]), a well-characterized genetic model of mania ([@bib29]).

Although some genes, cells, or neural circuits in mammals are suggested to have roles in homeostatic sleep regulation ([@bib19], [@bib21], [@bib31]), the detailed mechanisms remain largely unknown. On the other hand, some behaviors can overcome the homeostatic sleep pressure, even after long-lasting wakefulness. For example, SD induced by an environmental change such as cage exchange shows markedly less sleep rebound compared with gentle handling in mice ([@bib49]). VGAT-Cre^DTA/VMP^ mice did not show sleep rebound after SD ([Figure 2](#fig2){ref-type="fig"}D), indicating that either the VMP GABAergic neurons are critical for producing sleep states in response to SD or the behaviors induced by the loss of the neurons overcame the homeostatic sleep pressure induced by SD.

Increasing evidence indicates that dopamine and D~2~R promote wakefulness to suppress sleep ([@bib35], [@bib36], [@bib42], [@bib43]). In this study, using a constitutive genetic D~2~R KO ([Figure 3](#fig3){ref-type="fig"}), we clarified that sleep loss (promoting wake) in VGAT-Cre^DTA/VMP^ mice was dependent on D~2~R, at least during the light period ([Figure 4](#fig4){ref-type="fig"}). These data imply that the VMP GABAergic neurons suppress mainly dopaminergic systems and D~2~R to presumably prevent excessive amounts of wakefulness. It is unclear which dopaminergic systems are suppressed by the VMP. Anatomic studies ([@bib24], [@bib25], [@bib38], [@bib52]) indicate that the GABAergic VTA and rostromedial tegmental nucleus, both of which are included in the VMP, innervate dopaminergic neurons in the VTA and dorsal raphe nucleus (DRN), also known as the ventral periaqueductal gray matter, which regulate wakefulness ([@bib10], [@bib17], [@bib30], [@bib36], [@bib51]). The functional relationship between VMP and these dopaminergic areas should be examined in the future. Serotonin (5-HT) is also involved in regulating both sleep/wake and locomotor activity ([@bib12], [@bib45]). Studies in both humans and mice suggest that serotonin is involved in mania and its treatment ([@bib32], [@bib48]). In this sense, investigating the loss of VMP GABAergic innervation to DRN serotonergic neurons is another potential study direction.

The mechanisms related to hyperactivity, anti-depressive behaviors, and reduced sleep amount during the dark period in VGAT-Cre^DTA/VMP^ mice remain unclear. Recent studies revealed GABAergic projections from the VTA to the lateral hypothalamus ([@bib52], [@bib58]) and especially onto orexin neurons ([@bib11]), which are critical for maintaining wakefulness ([@bib8]). Optogenetic activation of GABAergic VTA terminals in the lateral hypothalamus suppresses wakefulness ([@bib11], [@bib58]). Moreover, lateral hypothalamic kindling induces mania-like behaviors ([@bib1]). Therefore, the lateral hypothalamus might play a role in the mania-like behaviors induced by GABAergic VMP ablation.

In summary, as illustrated in [Figure 4](#fig4){ref-type="fig"}J, our findings revealed that VMP GABAergic neurons are involved in various aspects of mania-like behaviors, and the reduced sleep amounts are mediated through the D~2~R-dependent dopaminergic system. Further research using VGAT-Cre^DTA/VMP^ mice may help to elucidate the different aspects of mania as well as the detailed neural mechanisms of sleep homeostasis and contribute to the development of safer and more effective drugs.

Limitations of the Study {#sec3.1}
------------------------

Pharmacological studies in VGAT-Cre^DTA/VMP^ mice, such as of lithium and valproic acid, which are the commonly used treatments for bipolar disorder ([@bib9], [@bib29]), are important for further investigation of the effects on individual behavioral phenotypes and D~2~R-dependency. Because all the experiments were performed using male mice in the present study, investigating the phenotypical difference with female mice provides further information about our findings.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for reagents and resources should be directed to and will be fulfilled by the Lead Contact, Yo Oishi (<oishi.yo.fu@u.tsukuba.ac.jp>).

### Materials Availability {#sec3.2.2}

The mouse line generated in this study (D~2~R KO strain) will be made available with a completed Material Transfer Agreement.

### Data and Code Availability {#sec3.2.3}

The data that support the findings of this study are available from the Lead Contact on reasonable request.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods and Figure S1
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